A Study to Evaluate the Safety and Efficacy of THR-317 for the Treatment of Diabetic Macular Oedema (DME)
Status:
Completed
Trial end date:
2018-04-01
Target enrollment:
Participant gender:
Summary
This study is conducted to evaluate the safety of THR-317 when administered intravitreally
and to assess the compound's efficacy in improving best-corrected visual acuity (BCVA) and
reducing central subfield thickness (CST) in subjects with centre-involved diabetic macular
oedema (DME).